Shattuck Labs (STTK) EBIT (2019 - 2026)
Shattuck Labs (STTK) posted quarterly EBIT of -$15.5 million for Q1 2026, down 8.03% year-over-year from -$16.9 million in Q1 2025, and down 16.26% quarter-over-quarter from -$13.4 million in Q4 2025.
Shattuck Labs (STTK) EBIT (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported EBIT for 8 consecutive years, with -$15.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 8.03% year-over-year to -$15.5 million; the TTM figure through Mar 2026 stood at -$52.7 million (up 29.7% YoY), while the FY2025 annual figure was -$51.5 million, up 36.07% from the prior year.
- EBIT slipped to -$15.5 million in Q1 2026 per STTK's latest filing, from -$13.4 million in the prior quarter.
- Across five years, EBIT topped out at -$10.7 million in Q3 2025 and bottomed at -$28.6 million in Q3 2023.
- Historically, EBIT has averaged -$20.2 million across 5 years, with a median of -$20.0 million in 2024.
- Annual changes were most pronounced in 2022 — EBIT sank 384.19% — and 2025, when it jumped 43.25%.
- Shattuck Labs' EBIT stood at -$26.3 million in 2022, then increased by 27.88% to -$19.0 million in 2023, then retreated by 3.64% to -$19.6 million in 2024, then soared by 31.92% to -$13.4 million in 2025, then fell by 16.26% to -$15.5 million in 2026.
- Business Quant data shows STTK's EBIT at -$15.5 million in Q1 2026, -$13.4 million in Q4 2025, and -$10.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | -16.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.16 Mn |
| Mar 31, 2026 | -15.55 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -10.72 Mn |
| Jun 30, 2025 | -13.03 Mn |
| Mar 31, 2025 | -14.39 Mn |
| Dec 31, 2024 | -19.64 Mn |
| Sep 30, 2024 | -17.92 Mn |
| Jun 30, 2024 | -22.96 Mn |
| Mar 31, 2024 | -20.04 Mn |
| Dec 31, 2023 | -18.95 Mn |
| Sep 30, 2023 | -28.60 Mn |
| Jun 30, 2023 | -22.75 Mn |
| Mar 31, 2023 | -21.66 Mn |
| Dec 31, 2022 | -26.28 Mn |
| Sep 30, 2022 | -25.23 Mn |
| Jun 30, 2022 | -27.66 Mn |
| Mar 31, 2022 | -24.17 Mn |
| Dec 31, 2021 | 9.25 Mn |
| Sep 30, 2021 | -17.58 Mn |